Drugs / Gusacitinib
Gusacitinib
also known as
ASN-002 · ASN-002 HYDROCHLORIDE · EN-3351 · EN-3351 HYDROCHLORIDE · GUSACITINIB HYDROCHLORIDE
Small molecule targets IFNG, SYK via inhibition
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03641573 | Oct 2018 | — | Asana BioSciences | Completed | No outcome recorded |
| Phase 1 | NCT03139981 | Apr → Nov 2017 | atopic eczema | Asana BioSciences | Completed | No outcome recorded |
| Phase 1 | NCT02853643 | Jul → Nov 2016 | — | Asana BioSciences | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03208296 | Dec 2017 → Dec 2024 | basal cell carcinoma | Ascend Biopharmaceuticals Ltd | Suspended | No outcome recorded |
| Phase 1/2 | NCT02550678 | Sep 2015 → Nov 2017 | nevoid basal cell carcinoma syndrome, nodular basal cell carcinoma | Ascend Biopharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 1/2 | NCT02440685 | May 2015 → Jun 2018 | B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma +2 | Asana BioSciences | Terminated | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04416516 | Jul 2020 → Feb 2024 | basal cell carcinoma, nevoid basal cell carcinoma syndrome | Ascend Biopharmaceuticals Ltd | Completed | No outcome recorded |
| Phase 2 | NCT03728504 | Jan 2019 → Apr 2020 | hand dermatosis | Asana BioSciences | Completed | No outcome recorded |
| Phase 2 | NCT03654755 | Sep 2018 → Oct 2019 | atopic eczema | Asana BioSciences | Terminated | No outcome recorded |
| Phase 2 | NCT03531957 | Jul 2018 → Jul 2019 | atopic eczema | Asana BioSciences | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06238531 Comparator | Jan 2025 | systemic lupus erythematosus | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Withdrawn | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gusacitinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06238531 ↗ |
| Known as | ASN-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04416516 ↗ |
| Known as | ASN-002 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594275 ↗ |
| Known as | EN-3351 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594275 ↗ |
| Known as | EN-3351 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594275 ↗ |
| Known as | GUSACITINIB HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594275 ↗ |
| Action | Inhibit | “Tyrosine-protein kinase SYK inhibitor” CHEMBL4594275 ↗ |
| Action | Restore | “The infected cells are able to transcribe and translate the IFNγ DNA” NCT03208296 ↗ |
| Modality | Small molecule | — CHEMBL4594275 ↗ |
| Route | Other | “protocol defined dose of ASN-002 as intra-tumoral injections” NCT02550678 ↗ |
| Target | IFNG | “This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells.” NCT04416516 ↗ |
| Target | SYK | “Tyrosine-protein kinase SYK inhibitor” CHEMBL4594275 ↗ |